Pemvidutide
Pemvidutide (ALT-801) is a GLP-1/glucagon dual receptor agonist developed by Altimmune for obesity with muscle mass preservation and NAFLD/NASH. Phase 2 MOMENTUM trial demonstrated significant weight loss with favorable body composition changes.
Pemvidutide (ALT-801) is a synthetic peptide dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors developed by Altimmune for the treatment of obesity and non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH). Its key differentiator from other incretin-based therapies is the preservation of lean body mass during weight loss, with a higher proportion of fat loss relative to total weight loss compared to selective GLP-1 receptor agonists.
Overview
Pemvidutide combines GLP-1 receptor agonism for appetite suppression and glucose-dependent insulin secretion with glucagon receptor agonism for hepatic lipid oxidation, increased energy expenditure, and preservation of lean body mass. The glucagon component stimulates amino acid metabolism and protein synthesis pathways that may counteract the lean mass loss typically observed with caloric restriction and GLP-1 agonist-mediated weight loss.
In clinical trials, pemvidutide has demonstrated that approximately 65% of weight lost is fat mass — a more favorable body composition outcome than the approximately 60-75% fat mass loss typically seen with GLP-1 receptor agonists alone (where 25-40% of weight lost may be lean mass). This distinction is clinically meaningful, as preservation of muscle mass during weight loss protects metabolic rate, functional capacity, and long-term weight maintenance.
Mechanism of Action
Pemvidutide engages two receptor pathways through coordinated physiological mechanisms:
GLP-1 Receptor Agonism: Pemvidutide activates GLP-1 receptors on pancreatic beta cells to stimulate glucose-dependent insulin secretion, suppress glucagon secretion at the pancreatic level, slow gastric emptying, and promote satiety through central nervous system receptor activation in the hypothalamus and brainstem. These effects contribute to both glycemic control and appetite suppression.
Glucagon Receptor Agonism: The glucagon component activates hepatic glucagon receptors to stimulate fatty acid beta-oxidation, reduce hepatic lipid content, and increase energy expenditure. Glucagon receptor activation increases resting metabolic rate, which may partially offset the decline in energy expenditure that accompanies weight loss. Critically, glucagon promotes amino acid catabolism at supraphysiological doses but at the therapeutic doses used in pemvidutide, it appears to support protein turnover and lean mass preservation.
Hepatic Lipid Oxidation: Glucagon receptor agonism directly drives hepatic fatty acid oxidation through activation of the cAMP-PKA signaling cascade, upregulating carnitine palmitoyltransferase 1 (CPT1) and other enzymes of mitochondrial beta-oxidation. This mechanism is particularly relevant for NAFLD/NASH, where pemvidutide can reduce liver fat content through both direct hepatic effects and indirect weight-loss-mediated improvements.
Lean Mass Preservation: The mechanism by which pemvidutide preserves lean mass relative to other anti-obesity agents is hypothesized to involve glucagon-mediated increases in energy expenditure (reducing the caloric deficit imposed on muscle protein), maintenance of protein synthesis signaling, and potential effects on growth hormone and IGF-1 axes. The net result is a shift in the composition of weight loss toward a higher proportion of fat mass.
Central Appetite Regulation: GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and food intake. The dual agonism may produce enhanced satiety compared to GLP-1 alone through complementary signaling mechanisms.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
MOMENTUM Phase 2 Obesity Trial
The MOMENTUM trial evaluated pemvidutide at multiple doses (1.2 mg and 1.8 mg weekly) in adults with obesity or overweight (BMI ≥27 with comorbidity). At 48 weeks, participants receiving pemvidutide 1.8 mg achieved mean body weight reduction of approximately 10.3%, with the key differentiator being favorable body composition: approximately 65% of weight lost was fat mass, suggesting meaningful preservation of lean body mass. The trial also demonstrated improvements in waist circumference, blood pressure, and lipid parameters. [Altimmune press release and Obesity 2023 presentations]
NAFLD/NASH (Liver Fat Reduction)
Pemvidutide has demonstrated significant reductions in liver fat content, consistent with the direct hepatic effects of glucagon receptor agonism. In a Phase 1b study in patients with hepatic steatosis, pemvidutide produced dose-dependent reductions in liver fat as measured by MRI-proton density fat fraction (MRI-PDFF). Reductions of up to 50-60% from baseline were observed, positioning pemvidutide as a potential treatment for NAFLD and NASH. The glucagon-mediated direct hepatic lipid oxidation provides a mechanism distinct from weight-loss-mediated liver fat reduction.
Body Composition Analysis
Dual-energy X-ray absorptiometry (DEXA) analysis from clinical trials confirmed that pemvidutide produces a higher ratio of fat mass loss to total weight loss compared to historical data from GLP-1 receptor agonist trials. This body composition advantage is clinically meaningful for several reasons: preserved lean mass maintains resting metabolic rate (reducing weight regain risk), protects against sarcopenia (particularly relevant in older adults), and maintains functional capacity and physical performance.
Cardiovascular Risk Factors
Across clinical studies, pemvidutide produced improvements in systolic blood pressure, triglycerides, and LDL cholesterol consistent with the magnitude of weight loss achieved. The dual mechanism may provide additional cardiovascular benefits through glucagon-mediated improvements in hepatic lipid metabolism.
Clinical Research Protocols
Pemvidutide's clinical development includes trials for obesity and NAFLD:
MOMENTUM Phase 2 Obesity Trial (NCT05295875): Randomized, double-blind, placebo-controlled, 48-week study evaluating pemvidutide 1.2 mg and 1.8 mg weekly in adults with BMI ≥30 (or ≥27 with comorbidity). Primary endpoint: percent change in body weight from baseline at 48 weeks. Secondary endpoints include body composition (DEXA), waist circumference, blood pressure, and metabolic parameters. Dose escalation protocol over initial weeks to target maintenance dose.
NAFLD Trial (NCT05646693): Phase 2 study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. Primary endpoint: change in liver fat content measured by MRI-PDFF. This trial leverages the direct hepatic effects of glucagon receptor agonism for liver fat reduction.
Dosing Protocol: Pemvidutide is administered as a once-weekly subcutaneous injection. Dose escalation from a starting dose to the target maintenance dose (1.2 mg or 1.8 mg) is used to mitigate gastrointestinal side effects.
Comparison to Related Compounds
| Parameter | Pemvidutide (1.8 mg) | Semaglutide 2.4 mg | Tirzepatide (15 mg) | Retatrutide (12 mg) | Survodutide |
|---|---|---|---|---|---|
| Receptor targets | GLP-1 + Glucagon | GLP-1 only | GIP + GLP-1 | GIP + GLP-1 + Glucagon | GLP-1 + Glucagon |
| Dosing frequency | Once weekly | Once weekly | Once weekly | Once weekly | Once weekly |
| Weight loss | ~10.3% (48 wk) | ~15.8% (68 wk) | ~22.5% (72 wk) | ~24.2% (48 wk, Phase 2) | ~14.9% (46 wk, Phase 2) |
| Lean mass preservation | Enhanced | Standard | Standard | Unknown | Unknown |
| Liver fat reduction | Significant (direct) | Moderate (indirect) | Moderate | Pronounced | Significant |
| Development stage | Phase 2 | Approved | Approved | Phase 3 | Phase 3 |
Pemvidutide vs. Semaglutide: Pemvidutide's total weight loss (~10.3%) is less than semaglutide 2.4 mg (~15.8%), but the body composition of weight loss may be more favorable, with greater fat mass loss relative to total weight loss. The glucagon component provides direct hepatic lipid oxidation effects that semaglutide lacks. For patients where lean mass preservation is a priority (older adults, sarcopenic obesity), pemvidutide's profile may be advantageous.
Pemvidutide vs. Tirzepatide: Tirzepatide produces substantially greater total weight loss through dual GIP/GLP-1 agonism. However, pemvidutide's glucagon component may provide superior liver fat reduction through direct hepatic mechanisms and better lean mass preservation. The two agents target different receptor combinations (GIP/GLP-1 vs GLP-1/glucagon).
Pemvidutide vs. Retatrutide: Retatrutide is a triple agonist that includes glucagon receptor activity alongside GIP and GLP-1. Compared to pemvidutide's dual GLP-1/glucagon mechanism, retatrutide adds GIP agonism, which may contribute to the greater total weight loss observed (24.2% vs ~10.3%). Both share the glucagon-mediated liver fat reduction advantage.
Pemvidutide vs. Survodutide (BI 456906): Both are GLP-1/glucagon dual agonists but differ in molecular design, dosing, and clinical focus. Survodutide (Boehringer Ingelheim) is more advanced in development and has shown greater weight loss in Phase 2 trials (~14.9% at 46 weeks). Both share the theoretical advantage of glucagon-mediated hepatic lipid oxidation for NASH/NAFLD.
Ongoing & Future Research
Pemvidutide's clinical development is focused on obesity and NAFLD:
-
MOMENTUM Phase 2b Extension (NCT05295875): Extended follow-up from the MOMENTUM trial to assess durability of weight loss, body composition changes, and long-term safety of pemvidutide in obesity.
-
NAFLD Phase 2 (NCT05646693): Evaluation of pemvidutide's effect on liver fat content and potential NASH resolution. Histological endpoints may be included in future Phase 3 designs.
-
Phase 3 Planning: Altimmune has indicated plans for Phase 3 trials in obesity and/or NAFLD, pending final Phase 2 data readouts. The body composition differentiation (lean mass preservation) is expected to be a key focus of the Phase 3 program.
-
Sarcopenic Obesity: Potential future studies in older adults with sarcopenic obesity, where the lean mass preservation profile of pemvidutide may provide particular clinical benefit.
Safety Profile
Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and decreased appetite, consistent with the GLP-1 receptor agonist class. These symptoms are typically mild to moderate, dose-dependent, and most prevalent during dose escalation. Discontinuation rates due to adverse events in Phase 2 trials were generally comparable to other incretin-based therapies. The glucagon component raises theoretical concerns about hyperglycemia, but clinical data show that GLP-1 receptor agonism counterbalances this effect, producing net improvements in glycemic control. Heart rate increases of 1-3 bpm have been observed. Standard incretin class precautions apply, including monitoring for pancreatitis and gallbladder disease. Long-term safety data beyond 48 weeks are not yet available.
Pharmacokinetic Profile
Pemvidutide — Pharmacokinetic Curve
Subcutaneous injection (once weekly)Quick Start
- Route
- Subcutaneous injection (once weekly)
Research Indications
Weight Loss
Dual GLP-1/glucagon receptor agonist. Phase 2 MOMENTUM trial demonstrated up to 15.6% weight loss at 48 weeks. The glucagon component enhances energy expenditure beyond GLP-1 effects alone.
Glucagon receptor agonism may promote preferential fat loss and relative lean mass preservation compared to GLP-1-only agonists, based on preclinical data and body composition analyses.
Metabolic
Phase 2 IMPACT trial showed significant liver fat reduction (up to 78% relative decrease) and improvements in fibrosis biomarkers. Glucagon receptor activation enhances hepatic lipid oxidation and reduces de novo lipogenesis.
Pemvidutide improved triglycerides and other lipid parameters in clinical trials, partially driven by glucagon-mediated hepatic lipid metabolism effects.
Despite glucagon component potentially raising glucose, the GLP-1 component provides net glycemic benefit. HbA1c improvements observed in patients with T2DM in phase 2 studies.
Research Protocols
subcutaneous Injection
Dosing Protocol: Pemvidutide is administered as a once-weekly subcutaneous injection.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| MOMENTUM Phase 2 Obesity Trial | 1.2 mg, 1.8 mg | Once weekly | 48 weeks |
| Dosing Protocol | 1.2 mg, 1.8 mg | Once weekly | —(Route: Subcutaneous Injection) |
Interactions
Peptide Interactions
Central Appetite Regulation: GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and food intake.
The two agents target different receptor combinations (GIP/GLP-1 vs GLP-1/glucagon).
Retatrutide: Retatrutide is a triple agonist that includes glucagon receptor activity alongside GIP and GLP-1.
What to Expect
What to Expect
Levels begin building after first administration; half-life of ~6-7 days (subcutaneous) means steady state reached over week 4-6
Primary endpoint: percent change in body weight from baseline at 48 weeks.
Initial response period as levels accumulate with repeated dosing
Steady-state concentrations expected after approximately 33 days of regular administration
Continued administration maintains therapeutic levels; effects may plateau at steady state
Quality Indicators
What to look for
- Phase 3 clinical trial data available
Caution
- Short half-life may require frequent dosing
Frequently Asked Questions
References (4)
- [1]Valenzuela-Vallejo, L. et al Novel Pharmacological Approaches for the Treatment of Obesity Metabolism (2023)
- [2]Ambery, P. et al MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes Lancet (2018)
- [3]Hope, D. C. D. et al Striking the Balance: GLP-1/Glucagon Co-Agonism for the Treatment of Obesity Front. Endocrinol. (2021)
- [4]Day, J. W. et al A new glucagon and GLP-1 co-agonist eliminates obesity in rodents Nat. Chem. Biol. (2009)
PEG-MGF
PEG-MGF (PEGylated Mechano-Growth Factor) is a modified form of IGF-1 that stimulates myoblast proliferation and differentiation, with research applications in muscle repair, cardiac protection, bone healing, and neuroprotection.
Pentapeptide-18
Pentapeptide-18 is the INCI designation for the enkephalin-analog neuromuscular peptide marketed as Leuphasyl by Lipotec, which reduces expression wrinkles by modulating presynaptic acetylcholine release through opioid receptor binding.